nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.11.2022 | editorial

Multiple sclerosis at the crossroads of scientific evidence and clinical translation

verfasst von: Prof. Dr. Johann Sellner, FAAN FEAN FANA MBA

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2022

Einloggen, um Zugang zu erhalten

Excerpt

Few neurological conditions have witnessed such a magnitude of clinical and therapeutic advances over recent years as multiple sclerosis (MS). In addition, there is now a greater understanding of the underlying genetic and environmental factors involved in the condition’s pathogenesis. Indeed, the causality of Epstein–Barr virus infection and the development of MS has been corroborated only recently. Moreover, the relevance of comorbidities for the disease course and individual quality of life is now acknowledged. Currently, there are efforts to translate the improved understanding of MS-related comorbidities into clinical practice. …

Nächster Artikel Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects

Olbert E, Struhal W. Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects. Wien Med Wochenschr. 2022; https://doi.org/10.1007/s10354-022-00925-2.CrossRefPubMed

Berek K, Paganini C, Hegen H, Bsteh G, Grams A, Auer M, et al. Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate. Wien Med Wochenschr. 2022; https://doi.org/10.1007/s10354-022-00913-6.CrossRefPubMed

Hegen H, Berek K, Deisenhammer F. Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity. Wien Med Wochenschr. 2022; https://doi.org/10.1007/s10354-022-00912-7.CrossRefPubMed

Arneth B, Kraus J. Experimental laboratory biomarkers in multiple sclerosis. Wien Med Wochenschr. 2022; https://doi.org/10.1007/s10354-022-00920-7.CrossRefPubMed

Voigt I, Stadelmann C, Meuth SG, Schipp B, Flachenecker P, Maurer M, et al. New master’s program: multiple sclerosis management. Wien Med Wochenschr. 2022; https://doi.org/10.1007/s10354-021-00900-3.CrossRefPubMedPubMedCentral

Trostel C, Laichinger K, Hauser TK, Saur S, Krumbholz M, Henes J, et al. Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever. Wien Med Wochenschr. 2021; https://doi.org/10.1007/s10354-021-00893-z.CrossRefPubMed

Ovchinnikov A, Findling O. An overview of pivotal trials and real-world evidence for CD20 depleting therapy in multiple sclerosis. Wien Med Wochenschr. 2022. https://doi.org/10.1007/s10354-022-00939-w.CrossRefPubMedPubMedCentral

Moser T, Ziemssen T, Sellner J. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr. 2022. https://doi.org/10.1007/s10354-022-00931-4.CrossRefPubMedPubMedCentral

Titel: Multiple sclerosis at the crossroads of scientific evidence and clinical translation
verfasst von: Prof. Dr. Johann Sellner, FAAN FEAN FANA MBA
Publikationsdatum: 01.11.2022
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 15-16/2022
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-022-00936-z

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2022

Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever

Neuer Masterstudiengang: Multiple Sklerose Management

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis

Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate